News 09.06.2021 Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") pursuant to a registration...
Events, Internal events
Event date: 17.06.2021
Date: 17th June 2021 (9am or 7pm CET)
Abstract:
A critical consideration in biopharmaceutical development labs is the overarching integration of bioreactors, novel sensor technologies and state-of-the art reference analyzers with the ultimate goal of smarter process control. In a real lab-environment in Tokyo, we demonstrated the effective use of the Lucullus...
News 02.06.2021 Schlieren (Zurich), Switzerland, June 2, 2021 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor networks both exceeding management expectations. Direct sales of MagnetOs in the U.S. accelerated in...
News 27.05.2021 Zurich-Schlieren, Switzerland, May 27, 2021. Molecular Partners (SIX: MOLN) and Novartis announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program...
Events, External events
Event date: 02.06.2021
Date: 2. June 2021
Start: 08.00 am CEST
Duration: 1 hour
Together with our experts, we share some insights on how you can build safe and reliable AI for health care and share some interesting real-world use cases.
More information and registration: https://bit.ly/3xEIiqS